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Knowledge of the karyotypes of cancer cells is the theoretical underpinning of diagnostic/prognostic DNA-cytometry.
Currently the translation is hampered by different terminologies of both fields. The following letter tries to close current
gaps between the two fields by harmonizing their different terminologies.
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Cytogenetics and DNA-cytometry both study the karyo-
typic basis of the malignant transformation of cells. Their
results are however rarely compared with each other, al-
though both could profit from such comparisons. On the
occasion of the excellent article by Bloomfield et al. in
Mol Cytogen 7:71 (2014) this letter tries to harmonize the
terminology of both fields to advance mutual understand-
ing and thus the impact of both fields.
With great interest and appreciation I have read the excel-
lent article: “Karyotypic evolutions of cancer species in rats
during the long latent periods after injection of nitrosurea”
by Bloomfield et al. in Molecular Cytogenetics, 7:71 (2014).
As a cytopathologist, dedicated to diagnostic and prog-
nostic DNA-image-cytometry for 30 years, I have been
interested to find out whether the „karyotypic-“ or
speciation-theory” of the malignant transformation of human
cells by Bloomfield et al. is consistent with my observations
on the occurrence and development of DNA-aneuploidy in
different types of non-neoplastic, preneoplastic and malignant
human lesions. The result is: Yes, if we make the following
translations:Clonal-/DNA-stemline aneuploidy =malignancy
What Bloomfield et al. call “clonal aneuploidy” corre-
sponds to “stemline aneuploidy” in DNA-cytometry. It
is 100% specific for malignancy. We could prove that if
DNA-aneuploidy is present in lesions that are not (yet)
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lesions will develop histologically detectable malignancy
within a few months to years [1-3]. We thus call these
lesions: “prospectively malignant” [4-6]. The clonal
aneuploidy/DNA-stemline-aneuploidy described by
Bloomfield et al. defines in our experience any tissue-
lesion as malignant or obligatory premalignant. The
Positive Predictive Value, PPV, of clonal aneuploidy to
develop histologically proven malignancy, if untreated, is
100%. Such lesions have to be treated immediately by
removal.
Non clonal-/DNA-single-cell aneuploidy = possible
malignancy
What Bloomfield et al. call “non clonal aneuploidy” results
in “single-cell aneuploidy” in DNA-image-cytometry. We
call these abnormal DNA-values of single cells “rare events”
(Figure 1). The detection of non clonal aneuploidy in atyp-
ical hyperplasias or dysplasias is associated with a lower
PPV in subsequent months as compared with DNA-
stemline-aneuploidy (e.g. 41,2% as compared to 76,3% for
Pap-smears: Grote et al., [3]). As this PPV is too high to be
left for surveillance only, we also recommend therapy of
the respective lesions or at least tight follow-up with re-
peated biopsies.
Number of abnormal clones/DNA-stemlines = grades
of malignancy
Number and abnormality of cytogenetic clonal
variants in a given cancer are equivalent of their genetic
flexibility. Such clones have their cytometric equivalent
in the number and abnormality of DNA-stemlines.is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0) which permits unrestricted use, distribution, and reproduction
properly credited. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Figure 1 Rare nuclei with abnormally high DNA-contents in c, correspondig to non-clonal aneuploidy. 1c = DNA-content of one haploid chromosomal
set. From a bile-duct brushing with in-situ cancer. Specifically stained for DNA according to Feulgen.
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tential of an individual cancer. They therefore are suited
as prognostic markers for grading the malignancy of
cancers [7-10].
DNA-stemlines, with clonal aneuploidy, are equally
well identified by image- and flow-cytometry Motherby
et al. [1]). Non clonal aneuploidy of single cells with
abnormally high nuclear DNA-contents, is however only
detected with sufficient sensitivity by image-cytometry
(Figure 1).From hyperplasia to malignancy
Hyperplasias and dysplasias do not generally, or a priori
contain non clonal or single cell aneuploidy, as they
can start as mere diploid hyperproliferations. Without
any type of aneuploidy they do not yet bear a clinically
relevant risk to become malignant. Yet, they are at risk
to develop aneuploidy. As long, as we do not detect any
type of aneuploidy in these lesions, we do not call them
“prospectively malignant” or “premalignant”. But, the
risk of a hyperplasia to become malignant is slightly in-
creased by the increased rate of proliferation, which is
associated with an increased risk to develop “non clonal
aneuploidy”. The risk of a hyperplasia with “non clonal
aneuploidy” (“single cell aneuploidy”) to develophistologically manifest cancer is already so high as to
justify clinical intervention [2,3].
Thus hyperproliferation in hyperplasias or dysplasias,
even without known carcinogens, are at risk to develop
non-clonal and subsequent clonal aneuploidies. As soon
as this has occurred, the lesion has to be considered as def-
initely malignant (= cancer, if it is derived from epithelial
cells).
Moreover, carcinogens are able to induce non clonal
aneuploidy (Figure 1) even without the occurrence of hy-
perplasias, as for example asbestos-induced mesothelioma,
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